A pharmaceutical research group sued the Trump administration to block a policy aimed at lowering drug prices by allow some prescription medications to be imported -- and re-imported -- into the U.S. from Canada.
The policy announced in July poses “significant safety risks” because it would allow the imports without manufacturers’ “authorization or oversight,” according to the complaint by Pharmaceutical Research and Manufacturers of America filed Monday in Washington federal court.
To contact the reporter on this story:
To contact the ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.